$STAA

STAAR Surgical (STAA) reported Q2 revenue of $93.54M, up 111% YoY, beating estimates by 3.3%. Inspire Medical (INSP) saw revenue drop 7.6% YoY but beat estimates, raising guidance. Enovis (ENOV) reported $582.8M in revenue, up 3.2%, missing full-year EPS guidance. Integer (ITGR) and Haemonetics (HAE) also reported Q2 results, with ITGR up 4.4% and HAE up 21.7% since reporting.

Analysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.

Staar Surgical (STAA) shares rose nearly 8% after Stifel's Thomas Stephan upgraded the stock to buy from hold, raising the price target to $31. He cited positive sales momentum, particularly in China, and potential for acquisitions. The company's FDA-approved products and lean operations were also highlighted.

Wall Street analyst research calls on Tuesday included upgrades for Kroger (KR), Netflix (NFLX), and others, while PepsiCo (PEP), Ryder Systems (R), and more were downgraded. Futures traded higher after a rough start to the week, with major indices closing lower. Treasury yields rose, oil prices surged, and gold and crypto markets declined.

Analysts updated price targets for several companies. Baird cut Boot Barn (BOOT) to $160, Stifel lowered Vail Resorts (MTN) to $157, Mizuho cut Stitch Fix (SFIX) to $2.5, BTIG boosted Robinhood (HOOD) to $135, Cantor Fitzgerald cut Western Union (WU) to $6, Deutsche Bank cut Netflix (NFLX) to $95, BNP Paribas cut Rollins (ROL) to $35, Stifel raised STAAR Surgical (STAA) to $31, B of A Securities cut Bending Spoons (BSP) to $36, BMO Capital raised American Eagle (AEO) to $20.

Stifel upgraded STAAR Surgical (STAA) to Buy, raising its price target to $31. The firm expects China-driven growth and improved market conditions to boost sales. STAA reported Q2 2026 revenue of $93.5M, beating estimates, but EPS missed. The stock trades at $20.87, below a Fair Value estimate of $26.45. Analysts have mixed outlooks, with targets ranging from $28 to $33.

STAAR Surgical (STAA) announced a $50M share repurchase program over 12 months, funded by free cash flow and cash on hand. The company has 50.1M shares outstanding as of August 2026. Analysts project revenues of $400M and earnings of $36.5M by 2029, assuming 11.3% yearly revenue growth. The buyback plan indicates management's focus on capital allocation amid demand and cost pressures in key markets like China.

STAAR Surgical appointed David Bailey, former CEO, as Chief Commercial Officer to lead EVO ICL business. Bailey previously grew international revenue to 74% and ICL revenue to $32 million. He will focus on expanding in Asia, South America, and Africa.

STAAR Surgical (NASDAQ:STAA) shares rose 2% after-hours after announcing a $50M share repurchase program. The medical device company plans to buy back shares over the next year, subject to market conditions. The authorization reflects confidence in its business and financial strength, according to the company.

STAAR Surgical (STAA) reported Q2 2026 net sales of $93.5M, up 111% YoY, with net income of $8.1M. China sales more than doubled to $52.3M, now over half of total revenue. CEO Warren Foust outlined plans for growth. Global sales rose 6% excluding China, and gross margin improved to 74.5%. The company ended the quarter with $181.5M in cash and no debt.